Fresenius Medical Care AG appointed Cassie McLean as a member of its Management Board, effective August 1, 2026. Ms. McLean assumes the role of Chief Executive Officer for the Care Delivery segment, succeeding Craig Cordola. She will oversee global clinic operations, including Fresenius Kidney Care in the U.S. and international divisions, with a reshaped mandate to enhance operational accountability and execution. The company operates in the healthcare industry, providing dialysis products and services for patients with renal diseases.

Fresenius Medical Care AG reported second quarter 2026 results with organic revenue growth of 5% to EUR 4,861 million and operating income excluding special items up 23% to EUR 569 million. Reported net income decreased by 3% to EUR 218 million due to a EUR 71 million impairment related to the recommended revocation of TAVNEOS marketing authorization. The company advanced its FME Reignite strategy, converting 227 U.S. clinics to the 5008X CAREsystem and exiting approximately 100 clinics as part of the FME25+ program, which generated EUR 67 million in additional sustainable savings. A second share buyback program totaling around EUR 1 billion was initiated on May 28, with 2,454,945 shares repurchased for EUR 94 million by June 30. The company reaffirmed its full-year 2026 outlook, expecting broadly flat revenue growth and operating income within a positive to negative mid-single digit percent range.

Fresenius Medical Care AG reported second-quarter 2026 operating income excluding special items of EUR 569 million, a 23% increase at constant currency compared to the prior year, surpassing market consensus of EUR 515 million. Group revenue rose 4% at constant currency to EUR 4,861 million, slightly exceeding the capital market expectation of EUR 4,792 million. The company confirmed its unchanged financial outlook for the full year 2026. Fresenius Medical Care AG operates in the healthcare industry, providing dialysis and related medical services.

Fresenius Medical Care announced BEACON-US, a research initiative evaluating clinical outcomes and patient experiences of high-volume hemodiafiltration (HVHDF) in U.S. routine practice. Early data indicate HVHDF reduces muscle cramps by 40%, with over 70% of treatments using AutoSub plus technology reaching the target convective volume of at least 23 liters per session. The therapy is associated with fewer hospitalizations, improved survival, and better treatment tolerability compared to conventional hemodialysis. This initiative supports the company's strategy to expand access to HVHDF across the United States. Fresenius Medical Care operates in the healthcare industry as a leading provider of products and services for individuals with kidney diseases.